These results suggest that LL37 forms complexes with self-DNA and autoantibodies in SLE-affected tissues, which can enable LL37 to act as an adjuvant and exert local interferogenic activity, revealed by the expression of Mx1. This evidence concerns the gene MX1 and systemic lupus erythematosus.